Key highlights
- FDA approval granted under Priority Review and Breakthrough Therapy Designation
- Clinical trials showed a 19% functional cure rate versus less than 1% for standard care
- Ionis to receive 10% to 12% tiered royalties on net sales and milestone payments from GSK
- Treatment indicated for adult CHB patients without cirrhosis and specific HBsAg levels
- Approval marks Ionis' third major FDA regulatory milestone in the 2026 calendar year
What Approval Was Received?
The U.S. Food and Drug Administration approved HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B virus infection. The indication specifically covers adult patients without cirrhosis who have been receiving nucleos(t)ide analogue reverse transcriptase inhibitor therapy for at least six months. Eligible patients must have suppressed HBV DNA and hepatitis B virus surface antigen levels at or below 3000 IU/ml, as confirmed by an authorized diagnostic test. The approval follows the FDA's decision to grant the application Priority Review and Breakthrough Therapy Designation, emphasizing the drug's potential as a transformative therapeutic option.
Why This Approval Matters
Chronic hepatitis B affects approximately 1.7 million people in the United States and remains a primary driver of global liver cancer cases. Historically, treatment options have required lifelong medication with minimal chances of a functional cure. HIBSAGO represents a shift in this landscape, utilizing RNA-targeted technology to help the patient's immune system control the virus. By achieving a 19% functional cure rate in Phase 3 B-Well trials—defined as undetectable viral DNA and surface antigens for 24 weeks post-treatment—the drug provides a significant clinical advantage over standard therapies that typically achieve less than 1% cure rates.
Business Overview and Pipeline
- Ionis maintains a collaborative development model, having licensed bepirovirsen to GSK in 2019
- The company has recently secured FDA approvals for ZANVASTRO in Alexander disease and TRYNGOLZA for hypertriglyceridemia
- European regulatory expansion is underway with the recent marketing authorization for DAWNZERA in hereditary angioedema
- The firm remains focused on antisense technology across various therapeutic areas including cardiovascular and neurology
- GSK continues to pursue regulatory submissions for HIBSAGO in additional global geographies
Financial Context
Ionis enters this commercial phase with a market capitalization of $7.36 billion and a reaffirmed 2026 revenue guidance of $875 million to $900 million. The HIBSAGO approval triggers eligibility for regulatory and sales milestone payments, adding to the company's capital position. Furthermore, the 10% to 12% tiered royalty structure on global net sales provides a recurring revenue stream as GSK commercializes the product. While the company anticipates a non-GAAP operating loss of $425 million to $475 million for the full year 2026 due to heavy R&D investment, the growing portfolio of approved medicines shifts the firm toward a more mature commercial profile.
Down 36.7% since our story on 21 Oct: $44.27 when we broke it → $28.01 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $44.38 |
|---|---|
| 20 Oct | $45.40 |
| 21 Oct | $44.27 |
| 22 Oct | $43.91 |
| 23 Oct | $42.93 |
| 26 Oct | $43.42 |
| 27 Oct | $43.96 |
| 28 Oct | $44.90 |
| 29 Oct | $44.39 |
| 30 Oct | $43.52 |
| 2 Nov | $41.24 |
| 3 Nov | $40.42 |
| 4 Nov | $40.15 |
| 5 Nov | $38.80 |
| 6 Nov | $39.42 |
| 9 Nov | $31.00 |
| 10 Nov | $28.19 |
| 11 Nov | $28.33 |
| 12 Nov | $27.31 |
| 13 Nov | $29.06 |
| 16 Nov | $28.01 |
| Date | Announcement | Amount |
|---|---|---|
| 20 Oct 2026 | U.S. FDA approval of Hibsago (bepirovirsen) for chronic hepatitis BSource: ir.ionis.com | – |
| 03 Sep 2026 | U.S. FDA approval of ZANVASTRO (zilganersen) for Alexander diseaseSource: ir.ionis.com | – |
| 24 Jun 2026 | U.S. FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemiaSource: ir.ionis.com | – |
| 23 Mar 2026 | U.S. FDA acceptance for Priority Review of New Drug Application for zilganersen in Alexander diseaseSource: ir.ionis.com | – |
| 26 Feb 2026 | U.S. FDA acceptance for Priority Review of supplemental New Drug Application for olezarsen in severe hypertriglyceridemiaSource: ir.ionis.com | – |
| 21 Jan 2026 | European Commission marketing authorization granted for DAWNZERA (donidalorsen) for hereditary angioedemaSource: otsuka.co.jp | – |
Management commentary
“About 1.7 million people in the U.S are living with chronic hepatitis B, and yet treatment options have been historically limited and the vast majority of people living with the chronic infection require lifetime care without achieving meaningful functional cure.”
| Share price | $44.27 |
|---|---|
| Market cap | $7.4B |
| Revenue (annual) | $944M |
| 1-month price change | -1.40% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Ionis Pharmaceuticals announcing the FDA approval of HIBSAGO for the treatment of chronic hepatitis B.
Track IONIS PHARMACEUTICALS INC live
Get the next IONIS PHARMACEUTICALS INC SEC filing seconds after it lands.




